Abatacept in relapsing polychondritis
Authors:
- 1 August 2013
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (8) , 1427-1429
Abstract
Key clinical characteristics of the subjects, all meeting the Michet criteria for RPC,4 are shown in table 1. Written informed consent was obtained from all subjects. Abatacept 125 mg subcutaneously weekly was planned to be administered for 24 weeks, but two subjects discontinued early: subject 001 developed worsening pulmonary and neurological disease and discontinued at …Keywords
This publication has 7 references indexed in Scilit:
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis & Rheumatism, 2011
- Abatacept for Rheumatoid Arthritis: A Cochrane Systematic ReviewThe Journal of Rheumatology, 2010
- Abatacept for relapsing polychondritisRheumatology, 2010
- Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patientsArthritis Care & Research, 2009
- Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritisArthritis & Rheumatism, 2002
- Relapsing PolychondritisAnnals of Internal Medicine, 1998
- Relapsing PolychondritisAnnals of Internal Medicine, 1986